Bashan Dror, President and CEO of Protalix BioTherapeutics ($PLX), made one open market purchase of company shares worth $101 thousand in the last year. His most recent buy occurred on December 19, 2025. This ranks him 2,153rd among nearly 5,000 insiders for purchase amounts, below the average of $1.5 million across about 3.3 transactions per insider. Dror reported no open market sales in the period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec. 19, 2025 | Protalix BioTherapeutics, Inc. | $PLX | Bashan Dror | PRESIDENT AND CEO | P | Common Stock | 56000 | $1.81 | 2,532,934.0000 | 80,814,564 | 2.26% | 0.07% |
| Sept. 3, 2025 | Protalix BioTherapeutics, Inc. | $PLX | Bashan Dror | PRESIDENT AND CEO | A | Common Stock | 195000 | $0.00 | 2,476,934.0000 | 81,271,610 | 8.55% | 0.24% |
| Sept. 3, 2025 | Protalix BioTherapeutics, Inc. | $PLX | Bashan Dror | PRESIDENT AND CEO | A | Stock Option (Right to Buy) | 340000 | $0.00 | 340,000.0000 | 81,271,610 | 9999.99% | 0.42% |
| April 1, 2024 | Protalix BioTherapeutics, Inc. | $PLX | Bashan Dror | PRESIDENT AND CEO | A | Common Stock | 263960 | $0.00 | 2,281,934.0000 | 73,036,569 | 13.08% | 0.36% |
| Oct. 19, 2023 | Protalix BioTherapeutics, Inc. | $PLX | Bashan Dror | PRESIDENT AND CEO | P | Common Stock | 48387 | $1.40 | 116,387.0000 | 83,782,679 | 71.16% | 0.06% |
| Oct. 19, 2023 | Protalix BioTherapeutics, Inc. | $PLX | Bashan Dror | PRESIDENT AND CEO | P | Common Stock | 16129 | $1.41 | 132,516.0000 | 83,782,679 | 13.86% | 0.02% |
| Aug. 15, 2023 | Protalix BioTherapeutics, Inc. | $PLX | Bashan Dror | President and CEO | A | Common Stock | 800000 | $0.00 | 1,953,458.0000 | 83,200,641 | 69.36% | 0.96% |